Online trial investigator result meetings - what about the investigators’ feedback?
Following the outbreak of the COVID-19 pandemic, we now see that investigator result meetings have changed their format to online interaction...
The value of generating early insights on your investigational drug
When pharmaceutical companies develop new medicines, they are required to comply with regulatory requirements by reporting and publishing their clinical results. Adhering to these...
Are you properly informing your trial patients on the clinical trial results?
The importance of keeping your trial patients well-informed. True patient-centricity is not only obtaining input from trial patients – it also involves ...
Initiatives facilitating the advancement of Patient and Public Involvement in drug development
Patient and Public Involvement (PPI) can improve clinical research success. PPI is defined as research that is carried out with or by patients and those who have experience of a condition...
Consequences of not listening to the patients in clinical trials
Are you overlooking patient feedback on your investigational drug? Interestingly, the pharmaceutical industry is one of the few industries where...
Patient preferences as input to medical product decision making
PREFER’s patient input to decision making under evaluation by EMA and EUnetHTA. At Clinigma®, we are always happy to follow the development of projects promoting patient engagement...